Southeast Renal Research Institute   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Chattanooga TN United States (2008)

Organization Overview

First Clinical Trial
2008
NCT00502268
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (4)

corticotropin (acthar) (1 trial)

doxercalciferol (hectorol) (1 trial)

fenoldopam (corlopam) (2 trials)

furosemide (lasix) (1 trial)

Drugs in Phase 3 Trials (2)

melatonin (1 trial)

mesna (mesnex) (1 trial)

Drugs in Phase 2 Trials (1)

penicillamine (cuprimine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 4)

Arteriovenous Fistula (Phase 2)

Calcinosis (Phase 4)

Diabetic Nephropathies (Phase 4)

Fistula (Phase 2)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Nephrosis (Phase 4)

Nephrotic Syndrome (Phase 4)

Parasomnias (Phase 3)

Proteinuria (Phase 4)

Renal Insufficiency (Phase 4)

Renal Insufficiency, Chronic (Phase 3)

Sleep Wake Disorders (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 7